## EGIDE

Euronext C - FR0000072373 – GID

- Egide benefits from its exposure to the Defense sector
- ✓ H1 sales + 16.1% (+ 14.3% cer)
- o Egide SA + 16.3% / USA + 20.8% / Santier + 10.7%
- ✓ H2 could suffer from difficulties in relaunching commercial approaches due to the Covid

During our last point, we indicated that the management is relatively confident due to its presence in key sectors and therefore partly protected. The figures prove it right with double-digit growth across all its entities.

For Egide USA, this is the 4th consecutive semester of double-digit growth, due in particular to continued sustained demand for power products from historical customers. The development of HTTC ceramic, for its part, has made it possible to position itself on thermal imaging in the United States and must increasingly focus on RF/MW.

Santier recovered after 3 semesters of decline and returned to its highest values since its acquisition.

Egide SA is benefiting from the return of thermal imaging but also of microwave frequencies (RF/MW), the order book of which began to recover in H2 2019.

Reduced to the book-to-build announced when the 2019 turnover was published, which was 1.09, Egide is moving ahead, which consolidates our expectation for 2020 of 9% growth. On this basis, this makes an increase in H2 of 2.7% which may seem prudent. However, it is necessary to take into consideration, as mentioned by management, the difficulties caused by the Covid in the pursuit of commercial deployment and discussions with prospects. In addition, the fire in Cambridge will have a negative impact in Q3, while everything is "repaired". In the meantime, part of the plating has been switched to Santier and Egide SA.

This first semester, which is the most important since the acquisition of Santier, even though the global economic environment has never been so disturbed, perhaps foreshadows what one could call the new Egide.

Indeed, we were wondering about the group's ability to develop its commercial scope. We have here perhaps the first signals that it is finally taking. We should not extrapolate the H1 to the H2, the management having itself identified certain risks, but the lines are moving.

Furthermore, in the current context, the sectors addressed by the group are good shock absorbers. In addition, the difficulties induced by the Covid in getting around may lead some customers to fall back on proximity rather than going to China. Egide being present in Europe and on both sides of the USA, this could be an asset. Finally, remember that management said it was optimistic a little over a month ago about the conclusion of contracts with new players in the next 12 months. These contracts could lead to production starts by mid-2021. If this is confirmed, it is a new element of visibility.

#### Conclusion.

Following this H1, we confirm our annual expectations, whereas we expected to revise them downwards due to the consequences of the health crisis. H2 will, of course, be disrupted compared to H1 for exogenous reasons, but this should not call into question the group's ability to approach equilibrium.

Overall, the signals are rather positive and the fact that the group addresses sectors such as Defense or Space is a supporting factor in the current context.

#### **Opinion & target price**

We take over the monitoring of Egide with a Buy opinion and a price target of  $\notin$  1.34.

#### **BUY** vs Under Review

GreenSo

#### H1 Sales + Conference Call

BPI Label – Innovative company- PEA-PME Eligible

TARGET	BEFORE
€ 1.34	Under Review
SHARE PRICE (7.22.20)	POTENTIAL
€ 0.76	+ <b>76.4%</b>
CAPITALISATION	FLOTTANT

€ 7.86m € 5.24m

Ratios		2019	2020e	2021e
EV/Sales		0,5	0,5	0,4
EV/EBIT		nr	43,0	20,2
P/E		nr	-57,4	29,3
P/CF		-5,9	19,5	6,7
Dividend Yield		0,0	0,0	0,0
Data per share	2018	<b>2019</b> e	2020e	2021e
EPS	-0,29	-0,27	-0,01	0,03
%Change	nr	nr	nr	nr
FCF	-0,06	-0,21	-0,06	0,01
%Change	nr	nr	nr	nr
Dividend	0,00	0,00	0,00	0,00
Income Statement (€m)	2018	<b>2019</b> e	2020e	2021e
Net Sales	31,7	31,8	34,6	36,4
%Change	2,7%	0,1%	9,0%	5,0%
EBITDA	0,5	-0,2	1,4	1,9
% Sales	1,5%	-0,7%	4,1%	5,3%
EBIT	-1,5	-2,2	0,4	0,8
% Sales	-4,8%	-6,9%	1,0%	2,1%
Net Result	-2,3	-2,8	-0,1	0,3
% Sales	-7,2%	-8,9%	-0,4%	0,7%
Cash Flow Statement (€m)	2018	2019e	2020e	2021e
FCF	-0,5	-2,2	-0,6	0,1
Net Debt	4,6	8,6	7,8	7,7
Shareholder Equity	11,0	10,4	10,2	10,5
Gearing	41,7%	82,5%	75,7%	73,0%
ROCE	-6,3%	-7,3%	1,3%	2,7%
Shareholders				
Vatel Capital			,2%	
Sigma Gestion			,2%	
Ostrum AM		- /	0%	
J.F. Collins		0,	9%	
Free Float		61	,8%	
Performances	2020	3m	6m	1 Year
Egide	-9,7%	15,2%	-11,2%	-23,5%
CAC Small	-14,2%	14,2%	-13,3%	-10,7%
12 months Low-High	0,41	1,12		
Liquidity	2020	3m	6m	1 Year
Cumulative volume (000)	4 141	2 768	3 984	5 317
% of capital	40,0%	26,7%	38,5%	51,4%
% of Free Float	60,1%	40,2%	57,8%	77,2%
/o of filee filoat				

Next Event


H1 results : 29th of september




### **Snapshot Egide**


Egide articulates its activity through two technologies that are glass-metal and ceramic cases which makes it one of the few actors in the world to control them. These housings make it possible to ensure perfect hermeticity in environments that may be subject to high thermal and / or atmospheric stresses. Egide provides highly resistant interconnection boxes in sensitive environments (Space, Defense, Security, Aeronautics, Telecommunications, Energy, ...), solutions that guarantee the optimal reliability of electronic systems or complex chips. In February 2017, the group acquired Santier, a US company specializing in the manufacture of dissipative components and materials.

### **Fondamental Matrix**





**Investment Profile** 



## Target Price & rating history

Date	Туре	Opinion	Price per share	Target Price
7/10/20	Company contact	Under Review	€ 0.912	
3/27/2020	Conf. Call	Under Review	€ 0.634	Under Review
3/26/2020	2019 Annual Results	Under Review	€ 0.66	Under Review
1/29/2020	2019 Sales	Neutral	€0.91	€ 1.3
12/12/2020	Contact	Neutral	€ 0.952	€ 1.49
9/27/2019	H1 resultats	Neutral	€ 0.928	€ 1.49
7/15/2019	H1 Sales	Neutral	€1.05	€1.49



# **Financial Data**

Income Statement (€ m)	2016	2017	2018	2019	2020e	<b>2021</b> e
Revenues	22,2	30,9	31,7	31,8	34,6	36,4
Purchase	9,1	12,3	12,6	13,1	14,3	15,0
Externals costs	3,7	5,0	4,7	4,8	5,0	5,3
Personnals Costs	9,2	13,1	13,5	13,7	13,4	13,7
EBITDA	-0,2	0,0	0,5	-0,2	1,4	1,9
Amortization	0,7	1,0	1,8	1,4	0,9	1,0
other	0,3	0,1	-0,2	-0,5	0,2	0,2
EBIT	-0,6	-0,8	-1,5	-2,2	0,4	0,8
Financial Result	-0,1	-0,8	-0,6	-0,6	-0,5	-0,5
Тах	0,0	-1,2	0,1	0,0	0,0	0,0
Net Result	-0,7	-0,4	-2,3	-2,8	-0,1	0,3

Balance Sheet (€ m)	2016	2017	2018	2019	2020e	<b>2021</b> e
Fixed Assets	5,7	9,1	8,3	11,6	9,9	9,7
Stock Inventories	3,8	6,3	6,5	7,5	7,7	8,1
Accounts Recevaible	5,2	7,0	5,9	6,5	6,7	7,1
Other Currents Assests	0,2	0,3	0,3	0,2	0,3	0,3
Cash & Equivalents	1,1	3,0	2,4	1,5	2,2	2,2
OTAL Assets	16,0	25,7	23,4	27,2	26,8	27,3
hareholders' Equity	6,2	12,7	11,0	10,4	10,2	10,5
Provisions	0,5	0,7	0,7	0,8	0,9	0,9
inancial Debt	5,4	7,0	6,9	6,9	6,8	6,7
Accounts Payables	3,9	5,3	4,8	5,9	5,8	6,1
TOTAL Liabilitites	16,0	25,7	23,4	27,2	26,8	27,3

Cash Flow Statements (€ m)	2016	2017	2018	2019	2020e	2021e
Cash Flow from Operating Activities	-0,1	-0,5	-0,2	-1,1	1,1	1,6
Change in Net Working Capital	1,2	0,9	-0,7	0,2	0,7	0,4
Cash Flow from Operations	-1,3	-1,4	0,4	-1,3	0,4	1,2
Cash Flow from Investing	-1,0	-6,2	-0,9	-0,9	-1,0	-1,1
Capital Increase	0,0	7,7	0,0	2,4	0,0	0,0
Funding Flow	0,6	2,2	0,8	0,6	1,3	-0,1
Cash Flow from Financing	0,6	9,6	-0,2	1,3	1,3	-0,1
Net Change in cash position	-1,7	2,0	-0,6	-0,9	0,7	0,0

RATIOS	2016	2017	2018	2019	<b>2020</b> e	<b>202</b> 1e
Ebitda Margin	-0,9%	0,1%	1,5%	-0,7%	4,1%	5,3%
EBIT Margin	-2,5%	-2,7%	-4,8%	-6,9%	1,0%	2,1%
Net Margin	-3,3%	-1,2%	-7,2%	-8,9%	-0,4%	0,7%
ROE	-11,8%	-2,9%	-20,8%	-27,1%	-1,3%	2,6%
ROCE	-3,4%	-3,1%	-6,3%	-7,3%	1,3%	2,7%
Gearing	69,2%	31,4%	41,7%	82,5%	75,7%	73,0%
FCF per share	-0,5	-0,3	-0,1	-0,2	-0,1	0,0
EPS (€)	-0,2	-0,5 0,0	-0,1 -0,3	-0,2	0,0	0,0
Dividend per share (€)	0,0	0,0	0,0	0,0	0,0	0,0
Dividen Yield	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
Distribution rate	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%

Estimates : GreenSome Finance 2019-2020-2021 with new shares



### **Rating Definition**

BUY	NEUTRAL	SELL
Upside > +10%	-10% < Upside < +10%	Upside < -10%

### Disclosures

Corporate Finance operation in progress or completed during the last 12 months	GreenSome Consulting and affiliate owns common equity securities of this subject company	Financial Analysis Contract	Notice to the company before publication	Liquidity Contract	Liquidity Provider
NO	NO	YES	YES	NO	NO

This publication was prepared by Greensome Finance on behalf of GreenSome Consulting. It is issued for informational purposes only and does not constitute a solicitation of orders to buy or sell securities mentioned therein.

The information contained in this publication and all opinions contained therein are based on sources believed reliable. However Greensome Consulting does not warrant the accuracy or completeness of this information and no one can rely. All opinions, projections and / or estimates contained in this publication reflect the decision of Greensome Consulting on the date and may be subject to change without notice. This publication is for informational purposes only to professional investors who are supposed to develop their own investment decisions without relying improperly on this publication. Investors must make their own judgments about the appropriateness of investing in any securities mentioned in this publication taking into account the merits and risks attached to them, their own investment strategy and their legal status, fiscal and financial. Past performance is by no means a guarantee for the future. Because of this publication, neither Greensome Consulting nor any of its officers or employees, cannot be held responsible for any investment decision. In accordance with the regulations and to prevent and avoid conflicts of interest with respect to any investment recommendations, Greensome Consulting has developed and maintains an effective operational management of conflicts of interest. The system for managing conflicts of interest is to prevent, with reasonable certainty, any breach of the principles and rules of professional conduct. It is constantly updated to reflect regulatory changes and changes in the activity of Greensome Consulting. Greensome Consulting intends at all times, act with respect for the integrity of the market and the primacy of the interests of its customers. To this end, Greensome Consulting has set up an organization's business and the procedures commonly called "Chinese Wall" whose purpose is to prevent the improper circulation of confidential information, and organizational and administrative arrangements to ensure transparency in situations likely to be perceived as conflicts of interest by investors. This publication is in terms of its distribution in the UK, only for people considered persons licensed or exempt under the Financial Services Act 1986 'n the United Kingdom or any regulations passed under it or to persons as described in section 11 (3) of the Financial Services Act 1986 (Investment Advertisement) (Exemptions) Order 1997 and is not intended to be distributed or communicated, directly or indirectly, to any other type of person. The distribution of this publication in other jurisdictions may be restricted by applicable law, and anyone who would come to be in possession of this book should learn and observe such restrictions.

> GreenSome Consulting 86, rue de Monceau 75008 Paris, France RCS Paris : 529 571 259 Listing Sponsor Euronext Growth